Sign inCreate account

Report workspace

Add to folder
NCT01146327COMPLETEDanonymous

A Phase 1, Parallel, Randomized Trial To Assess The Effect Of Time Of Dosing On The Pharmacodynamics, Pharmacokinetics, Safety And Tolerability Of Multiple Oral Doses Of PF-04620110 In Otherwise Healthy Overweight Or Obese Adult Subjects

Sponsor

Source record

Pfizer

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

PF-04620110 is a novel compound targeting mechanisms involved in glucose metabolism, potentially acting on pathways related to insulin sensitivity and secretion, although specific molecular targets have not been disclosed.

Indication / condition

AI-normalized

Healthy

Intervention

Source record

PF-04620110, PF-04620110, PF-04620110, PF-04620110, Placebo

Source & freshness

Source record

NCT ID

NCT01146327

Original source

ClinicalTrials.gov

Source last updated

Apr 19, 2011

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01146327

Title

A Phase 1, Parallel, Randomized Trial To Assess The Effect Of Time Of Dosing On The Pharmacodynamics, Pharmacokinetics, Safety And Tolerability Of Multiple Oral Doses Of PF-04620110 In Otherwise Healthy Overweight Or Obese Adult Subjects

Sponsor

Pfizer

Status

COMPLETED

Phase

Phase 1

Condition raw

Healthy

Condition normalized

Healthy

Modality raw

small molecule

Modality normalized

small molecule

Target raw

PF-04620110 is a novel compound targeting mechanisms involved in glucose metabolism, potentially acting on pathways related to insulin sensitivity and secretion, although specific molecular targets have not been disclosed.

Target normalized

PF-04620110 is a novel compound targeting mechanisms involved in glucose metabolism, potentially acting on pathways related to insulin sensitivity and secretion, although specific molecular targets have not been disclosed.

Interventions

PF-04620110, PF-04620110, PF-04620110, PF-04620110, Placebo

Public preview

Source record

PF-04620110 is positioned within the competitive landscape of Type 2 diabetes treatments, targeting overweight and obese populations. Given the increasing prevalence of Type 2 diabetes globally, the asset holds significant commercial potential. The trial's completion indicates that Pfizer is advancing its pipeline in this therapeutic area, which is critical for maintaining market share against established players like Novo Nordisk and Sanofi. The collaboration with Bristol-Myers Squibb may enhance development capabilities and market access. However, the competitive landscape remains robust, necessitating a thorough assessment of efficacy and safety data to ensure differentiation.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1, Parallel, Randomized Trial To Assess The Effect Of Time Of Dosing On The Pharmacodynamics, Pharmacokinetics, Safety And Tolerability Of Multiple Oral Doses Of PF-04620110 In Otherwise Healthy Overweight Or Obese Adult Subjects

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT01146327

Status

COMPLETED

Phase

Phase 1

Sponsor

Pfizer

Executive brief

Investment-Ready Snapshot

PF-04620110 is positioned within the competitive landscape of Type 2 diabetes treatments, targeting overweight and obese populations. Given the increasing prevalence of Type 2 diabetes globally, the asset holds significant commercial potential. The trial's completion indicates that Pfizer is advancing its pipeline in this therapeutic area, which is critical for maintaining market share against established players like Novo Nordisk and Sanofi. The collaboration with Bristol-Myers Squibb may enhance development capabilities and market access. However, the competitive landscape remains robust, necessitating a thorough assessment of efficacy and safety data to ensure differentiation.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 19, 2011
Internal syncJun 17, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01146327

Indication

Healthy

Modality

small molecule

Target

PF-04620110 is a novel compound targeting mechanisms involved in glucose metabolism, potentially acting on pathways related to insulin sensitivity and secretion, although specific molecular targets have not been disclosed.

Intervention

PF-04620110, PF-04620110, PF-04620110, PF-04620110, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.